evolocumab

添付資料一覧

アステラス・アムジェン・バイオファーマ株式会社

第3部　品質に関する文書

3.2　データ又は報告書

3.2.S　原薬

資料番号	資料表題	著者	実施期間	試験実施場所	評価・参考
3.2.S	原薬	Amgen	—	Amgen	評価

3.2.P　製剤

資料番号	資料表題	著者	実施期間	試験実施場所	評価・参考
3.2.P	製剤	Amgen	—	Amgen	評価

3.2.A　その他

資料番号	資料表題	著者	実施期間	試験実施場所	評価・参考
3.2.A	その他	Amgen	—	Amgen	評価

第3部　品質に関する文書
3.3 参考文献

資料番号	著者・表題・出典
3.3-1	Abifadel M, Varret M, Rabes J-P, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-156.
3.3-2	Antes B, Amon S, Rizzi A, et al. Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector function. J Chromatogr B. 2007;852:250-256.
3.3-3	Bam NB, Cleland JL, Yang J, et al. Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. J Pharm Sci. 1998;87(12):1554-1559.
3.3-4	Bassett EW, Tanenbaum SW, Pryzwansky K, Beiser SM, Kabat EA. Studies on human antibodies. J Exp Med. 1965;122(2):251-261.
3.3-5	Bianchi AA, McGrew JT. High-level expression of full-length antibodies using trans-complementing expression vectors. Biotech and Bioeng. 2003;84:439-444.
3.3-6	Bjellqvist B, Hughes G, Pasquali C, et al. The focusing positions of polypeptides in immobilized pH gradients can be predicated from their amino acid sequences. Electrophoresis. 1993;14:1023-1031.
3.3-7	Boshart M, Weber F, Jahn G, Dorsch-Hasler K, Fleckenstein B, Schaffner W. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell. 1985;41:521-530.
3.3-8	Bradshaw RA, Brickey WW, Walker KW. N-Terminal processing: the methionine aminopeptidase and Na-acetyl transferase families. Trends Biochem Sci. 1998;23:263-267.
3.3-9	Brown MS, Goldstein JL. Lowering LDL – not only how low, but how long? Science. 2006;311:1721-1723.
3.3-10	Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res. 2008;49:394-398.
3.3-11	Chang BS, Kendrick BS, Carpenter JF. Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. J Pharm Sci. 1996;85(12):1325-1330.
3.3-12	Chelius D, Jing K, Lueras A. Formation of pyroglutamic acid from N-terminal glutamic acid in immunoglobulin gamma antibodies. Anal Chem. 2006;78:2370-2376.
3.3-13	Chen M, Cook KD. Oxidation artifacts in the electrospray mass spectrometry of Ab peptide. Anal Chem. 2007;79(5):2031-2036.
3.3-14	Chusainow J, Yang YS, Yeo JHM, et al. A study of monoclonal antibody-producing CHO cell lines: what makes a stable high producer? Biotech and Bioeng. 2008;102(4):1182-1196.
3.3-15	Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37:161-165.
3.3-16	Cohen JC, Boerwinkle E, Mosley TH, Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272.
3.3-17	Connell-Crowley L, Nguyen T, Bach J, et al. Cation exchange chromatography provides effective retrovirus clearance for antibody purification processes. Biotech and Bioeng. 2012;09(1):157-165.
3.3-18	Connelly S, Manley JL. A functional mRNA polyadenylation signal is required for transcription termination by RNA polymerase II. Genes Dev. 1988;2: 440-452.
3.3-19	Cunningham D, Dabley DE, Geoghegan KF, et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Bio. 2007;14(5):413-419.
3.3-20	Davies MV, Kaufman RJ. The sequence context of the initiation codon in the encephalomyocarditis virus leader modulates efficiency of internal translation initiation. J Virol. 1992;66(4):1924-1932.
3.3-21	Diepold K, Bomans K, Wiedmann M, et al. Simultaneous assessment of Asp isomerization and Asn deamidation in recombinant antibodies by LC-MS following incubation at elevated temperatures. PLoS ONE. 2012;7(1):1-10.
3.3-22	Dillon TM, Bondarenko PV, Rehder DS, Pipes GD, Kleemann GR, Ricci MS. Optimization of a reversed-phase high-performance liquid chromatography/mass spectrometry method for characterizing recombinant antibody heterogeneity and stability. J Chromatogr A. 2006;1120:112-120.
3.3-23	Dillon TM, Ricci MS, Vezina C, et al. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem. 2008; 283(23):16206-16215.
3.3-24	Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004;24:1454-1459.

3.3-25	Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82:70-77.
3.3-26	Food and Drug Administration. Inactive Ingredient Database [database online]. Retrieved 16 August 2012. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ucm080123.htm
3.3-27	Frangione B, Milstein C, Pink JRL. Structural Studies of Immunoglobulin G. Nature. 1969;221:145-148.
3.3-28	Fuller RS, Funnell BE, Komberg A. The dnaA protein complex with the E. coli chromosomal replication origin (oriC) and other DNA sites. Cell. 1984;38:889-900.
3.3-29	Galfre G, Milstein C. Preparation of Monoclonal Antibodies: Strategies and Procedures. Methods Enzymol. 1981;73: 3-46.
3.3-30	Garber E, Demarest SJ. A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem and Biophys Res Commun. 2007;355:751-757.
3.3-31	Gefroh E, Dehghani H, McClure M, Connell-Crowley L, Vedantham G. Use of MMV as a single worst-case model virus in viral filter validation studies. PDA J Pharm Sci Technol. 2014;68(3):297-311.
3.3-32	Gingeras TR, Sciaky D, Gelinas RE, et al. Nucleotide sequences from the adenovirus-2 genome. J Biol Chem. 1982;257(22):13475-13491.
3.3-33	Goetze AM, Liu YD, Zhang Z, et al. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology. 2011;21(7):949-959.
3.3-34	Goetze AM, Liu YD, Arroll T, Chu L, Flynn GC. Rates and impact of human antibody glycation in vivo. Glycobiology. 2012;22(2):221-234.
3.3-35	Graf LH, Chasin LA. Direct demonstration of genetic alterations at the dihydrofolate reductase locus after gamma irradiation. Mol Cell Biol. 1982;2:93-96.
3.3-36	Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation. 2004;110:227-239.
3.3-37	Gu S, Wen D, Weinreb PH, et al. Characterization of trisulfide modification in antibodies. Anal Biochem. 2010;400:89-98.
3.3-38	Harris JR. Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture. J Chromatogr A. 1995;705:129-134.
3.3-39	Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007;193:445-448.
3.3-40	Hornbeck P. Assays for Antibody Production. Current Protocols in Immunology. 1991:2.1.1-2.1.22.
3.3-41	Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50:S172-S177.
3.3-42	Jakobovits A, Kucherlapati R, Klapholz S, Mendez M, Green L, inventors; Abgenix, Inc., applicant. Transgenic mammals having human Ig loci including plural VH and Vk regions and antibodies produced therefrom. International application number PCT/US97/23091. International publication number WO 98/24893. International publication date: 11 June 1998.
3.3-43	Jefferis R, Lund J, Pound J. IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunological Reviews. 1998;163:59-76.
3.3-44	Jiang Y, Narhi LO. Applying selective biophysical techniques in assessing the comparability of protein therapeutics – case studies. Biophysical Techniques. 2006:1-6.
3.3-45	Jiang X, Song A, Bergelson S, et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov. 2011;10:101-110.
3.3-46	Johnson KA, Paisley-Flango K, Tangarone BS, Porter TJ, Rouse JC. Cation exchange-HPLC and mass spectrometry reveal C-terminal amidation of an IgG1 heavy chain. Anal Biochem 2007;360:75-83.
3.3-47	Jones LS, Kaufmann A, Middaugh CR. Silicone oil induced aggregation of proteins. J Pharm Sci. 2005;94(4):918-927.
3.3-48	Kao FT, Puck TT. Genetics of somatic mammalian cells VII. Induction and isolation of nutritional mutants in Chinese hamster cells. Proc Nat Acad Sci. 1968;60:1275-1281.
3.3-49	Kao Y-H, Hewitt D, Trexler-Schmidt M, Laird MW. Mechanism of antibody reduction in cell culture production processes. Biotech and Bioeng. 2010;107(4):622-632.
3.3-50	Kaufman RJ, Davies MV, Wasley LC, Michnick D. Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus. Nucleic Acids Res. 1991;19(16):4485-4490.
3.3-51	Khor HK, Jacoby ME, Squier TC, Chu GC, Chelius D. Identification of methionine sulfoxide diastereomers in immunoglobulin gamma antibodies using methionine sulfoxide reductase enzymes. MAbs. 2010;2(3):299-308.
3.3-52	Kozak M. The scanning model for translation: an update. J Cell Biol. 1989;108: 229-241.
3.3-53	Lagace TA, Curtis DE, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest. 2006;116:2995-3005.

3.3-54	Lopez D. PCSK9: An enigmatic protease. Biochimica et Biophysica Acta. 2008;1781:184-191.
3.3-55	Magnusson CGM, Bjornstedt M, Holmgren A. Human IgG is substrate for the thioredoxin system: differential cleavage pattern of interchain disulfide bridges in IgG subclasses. Mol Immunol. 1997;34(10):709-717.
3.3-56	Mayne J, Dewpura T, Raymond A, et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis. 2008;7(22):1-9.
3.3-57	McNutt MC, Lagace TA, Horton JD. Catalytic activity is not required for secreted PCSK9 to reduce LDL receptors in HepG2 cells. J Biol Chem. 2007;282:20799-20803.
3.3-58	Mendez MJ, Green LL, Corvalan JRF, et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nature Genetics. 1997;15:146-156.
3.3-59	Morris AE, Lee C, Thomas JN, inventors. Expression augmenting sequence elements (EASE) for eukaryotic expression systems. US patent 6,312,951. 06 November 2001.
3.3-60	Mousavi SA, Berge KE, Leren TP. The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis (review). J Intern Med. 2009;266:507-519.
3.3-61	Nimmerjahn F, Ravetch JV. Fcg receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34-47.
3.3-62	Pace CN, Vajdos F, Fee L, Grimsley G, Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 1995;4:2411-2423.
3.3-63	Pain R. Determining the CD spectrum of a protein. Current Protocols in Protein Science. 2004;Unit 7.6:7.6.1-7.6.24.
3.3-64	Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem. 2004;279(48):50630-50638.
3.3-65	Prigge ST, Kolhekar AS, Eipper BA, Mains RE, Amzel LM. Amidation of bioactive peptides: The structure of peptidylglycine a-hydroxylating monooxygenase. Science. 1997;278:1300-1305.
3.3-66	Pristatsky P, Cohen SL, Krantz D, Acevedo J, Ionescu R, Vlasak J. Evidence for trisulfide bonds in a recombinant variant of a human IgG2 monoclonal antibody. Anal Chem. 2009;81:6148-6155.
3.3-67	Rashid S, Curtis DE, Garuti R, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. PNAS. 2005;102(15):5374-5379.
3.3-68	Rasmussen B, Davis R, Thomas J, Reddy P. Isolation, characterization and recombinant expression in Veggie-CHO: A serum-free CHO host cell line. Cytotechnology. 1998;28:31-42.
3.3-69	Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292(3):344-350.
3.3-70	Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715-725.
3.3-71	Schlatter S, Stansfield SH, Dinnis DM, Racher AJ, Birch JR, James DC. On the optimal ratio of heavy to light chain genes for efficient recombinant antibody production by CHO cells. Biotechnol Prog. 2005;21(1):122-133.
3.3-72	Schuck P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys J. 2000;78:1606-1619.
3.3-73	Seidah NG, Prat A. The proprotein convertases are potential targets in the treatment of dyslipidemia. J Mol Med. 2007;85:685-696.
3.3-74	Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012;11:367-383.
3.3-75	Stoner MR, Fischer N, Nixon L, et al. Protein–solute interactions affect the outcome of ultrafiltration/diafiltration operations. J Pharm Sci. 2004;93(9):2332-2342.
3.3-76	Subramani S, Mulligan R, Berg P. Expression of the mouse dihydrofolate reductase complenentary deoxyribonucleic acid in simian virus 40 vectors. Mol Cell Biol. 1981;1(9):854-864.
3.3-77	Sutcliffe JG. Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322. Proc Natl Acad Sci. 1978;75(8):3737-3741.
3.3-78	Thirumangalathu R, Krishnan S, Ricci MS, Brems DN, Randolph TW, Carpenter JF. Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution. J Pharm Sci. 2009;98(9):3167-3181.
3.3-79	Tous GI, Wei Z, Feng J, et al. Characterization of a novel modification to monoclonal antibodies: Thioether cross-link of heavy and light chains. Anal Chem. 2005;77(9):2675-2682.
3.3-80	Trexler-Schmidt M, Sargis S, Chiu J, et al. Identification and Prevention of Antibody Disulfide Bond Reduction During Cell Culture Manufacturing. Biotechnol Bioeng. 2010;106(3):452-461.
3.3-81	Urlaub G, Chasin LA. Isolation of Chinese hamster cell mutants lacking dihydrofolate reductase activity. Proc Natl Acad Sci. 1980;77:4216-4220.
3.3-82	Valliere-Douglas J, Kodama P, Mujacic M, et al. Asparagine-linked oligosaccharides present on a non-consensus amino acid sequence in the CH1 domain of human antibodies. J Biol Chem. 2009;284(47):32493-32506.

3.3-83	Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol. 2006;24(10):1241-1252.
3.3-84	Wang W, Singh S, Zeng DL, King K, Nema S. Antibody structure, instability, and formulation. J Pharm Sci. 2007;96(1):1-26.
3.3-85	Wypych J, Li M, Guo A, et al. Human IgG2 Antibodies Display Disulfide-mediated Structural Isoforms. J Biol Chem. 2008;283:16194-16205.
3.3-86	Yoo EM, Wims LA, Chan LA, Morrison SL. Human IgG2 can form covalent dimers. J Immunol. 2003;170:3134-3138.
3.3-87	Zhang W, Czupryun MJ. Free sulfhydryl in recombinant monoclonal antibodies. Biotechnol Prog. 2002;18:509-513.
3.3-88	Zhang D-W, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007;282:18602-18612.
3.3-89	Zhang Z, Pan H, Chen X. Mass spectrometry for structural characterization of therapeutic antibodies. Mass Spectrom Rev. 2009;28:147-176.
3.3-90	Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79:514-523.

第4部　非臨床試験報告書
4.2　試験報告書
4.2.1　薬理試験
4.2.1.1　効力を裏付ける試験

資料番号	資料表題	著者	実施期間 （月／日／年）	試験実施場所	評価・参考
4.2.1.1-1	Study R20080178 - Binding Analysis of AMG 145 to Human, Cynomolgus Monkey, Hamster and Mouse PCSK9	[redacted]	[redacted]	Amgen Inc., South San Francisco, CA	評価
4.2.1.1-2	Study R20080177 - In Vitro IC50 Determination for AMG 145 and 31H4.2 in the LDLR:PCSK9 Binding Assay	[redacted]	Experiment 144-[redacted]: [redacted] Experiment 476-[redacted]: [redacted]	Amgen Inc., South San Francisco, CA	評価
4.2.1.1-3	Study R20080176 - In Vitro EC50 Determination for AMG 145 and 31H4.2 in the Cell LDL Uptake Assay	[redacted]	VBS Portion: [redacted]	Amgen Inc., South San Francisco, CA	評価
4.2.1.1-4	Study R20080222 - Effect of Anti-PCSK9 Antibody and Statin Combination on LDL Receptor Levels in HepG2 Cells	[redacted]	[redacted]	Amgen Inc., South San Francisco, CA	評価
4.2.1.1-5	Study R20080179 - Effect of a Single Subcutaneous Administration of AMG 145 on serum Cholesterol and Hepatic LDLR Regulation in Golden Syrian Hamsters	[redacted]	Experiment 144-[redacted]: [redacted] Experiment 476-[redacted]: [redacted]	Amgen Inc., South San Francisco [redacted] (In-Life)	評価
4.2.1.1-6	Study R20090025 - Effect of a Single Subcutaneous Administration of AMG 145 on Serum Lipids in Cynomolgus Monkeys	[redacted]	VBS Portion: [redacted]	[redacted] (In-Life) Amgen Inc., South San Francisco, CA	評価
4.2.1.1-7	Study R20090001 - Cholesterol Lowering Using 1A12, 23B5, or AMG 145 Antibodies Against PCSK9 in Male C57Bl/6 Mice Expressing Human PCSK9 by Adeno-associated Virus	[redacted]	[redacted]	Amgen Inc., South San Francisco, CA	評価
4.2.1.1-8	Study R20090266 - Effect of 8A3, 23B5, or AMG 145 on Serum Cholesterol in Male Cynomolgus Monkeys	[redacted]	VBS Portion: [redacted]	[redacted] (In-Life) Amgen Inc., South San Francisco, CA	評価
4.2.1.1-9	Study R20100042 - Cholesterol Lowering Using 8A3, 1A12, 9C9, or AMG 145 Antibodies Against PCSK9 in Male C57Bl/6 Mice Expressing Human PCSK9 by Adeno-associated Virus	[redacted]	[redacted]	Amgen Inc., South San Francisco, CA	評価

4.2.1.1-10	Study R20110022 - Effect of a Single Subcutaneous Administration of AMG 492 on Serum Lipids in Male Cynomolgous Monkeys	[redacted]	VBS Portion: [redacted] -	[redacted] (In-Life) Amgen Inc., South San Francisco, CA	評価

4.2.1.2 副次的薬理試験

資料番号	資料表題	著者	実施期間（月／日／年）	試験実施場所	評価・参考
4.2.1.2-1	Study 118361 – Cerivastatin-Mediated Myopathy in Female Sprague Dawley Rats	[redacted]	[redacted] - [redacted]	Amgen Inc., Seattle, WA	評価

4.2.1.3 安全性薬理試験

資料番号	資料表題	著者	実施期間（月／日／年）	試験実施場所	評価・参考
4.2.1.3-1	Study 110150 – Single-Dose Cardiovascular Study with Respiratory Rate and Neurobehavioral Evaluation of AMG 145 Administered by Intravenous Injection to Telemetry-Instrumented Conscious Male Cynomolgus Monkeys	[redacted]	[redacted] - [redacted]	[redacted]	評価

4.2.2 薬物動態試験

4.2.2.1 分析法及びバリデーション報告書

資料番号	資料表題	著者	実施期間（月／日／年）	試験実施場所	評価・参考
4.2.2.1-1	Study 112922 (MET-002532) - Method Validation of an ECL Immunoassay for the Quantification of AMG 145 in Hamster Serum Study	[redacted]	[redacted] - [redacted]	Amgen Inc., Seattle, WA	評価
4.2.2.1-2	Study 115227 ([redacted]-PMX2) - Method Transfer Validation for the Quantification of AMG 145 in Normal Hamster Serum by Electrochemiluminescence (ECL) Immunoassay	[redacted]	[redacted] - [redacted]	[redacted]	評価
4.2.2.1-3	Study 110599 - Method Qualification of an ELISA Method for Determining Free PCSK9 Concentrations in Cynomolgus Monkey or Human Serum and Plasma	[redacted]	[redacted] - [redacted]	Amgen Inc., Seattle, WA	評価
4.2.2.1-4	Study 116170 ([redacted]-JFV2) - Method Transfer Validation of an ELISA for the Quantification of PCSK9 in Cynomolgus Monkey Serum **(RE-ISSUE)**	[redacted]	[redacted] - [redacted]	[redacted]	評価
4.2.2.1-5	Study 111318 (MET-002332)- Method Validation of the Determination of AMG 145 in Cynomolgus Monkey serum by ELISA	[redacted]	[redacted] - [redacted]	Amgen Inc., Seattle, WA	評価

4.2.2.1-6	Study 115226 ([redacted]-QMX2) - Method Transfer Validation of the Quantification of AMG145 in Normal, Maternal and Infant Cynomolgus Monkey Serum and Cynomolgus Monkey Milk by Electrochemiluminescense (ECL) Immunoassay	[redacted]	[redacted] - [redacted]	Amgen Inc., Seattle, WA	評価
4.2.2.1-7	Study 113479 - Method Transfer Validation of an ELISA for the Quantification of AMG 145 in Cynomolgus Monkey Serum	[redacted]	[redacted] - [redacted]	[redacted]	評価
4.2.2.1-8	Study 115693 - Quantitative Determination of Rosuvastatin in Cynomolgus Monkey Plasma (EDTA) by LC/MS/MS	[redacted]	[redacted] - [redacted]	[redacted]	評価

4.2.2.2 吸収

資料番号	資料表題	著者	実施期間（月／日／年）	試験実施場所	評価・参考
4.2.2.2-1	Study 111322 - A Pharmacokinetic/Pharmacodynamic Study of AMG 145 in Naïve Male Cynomolgus Monkeys	[redacted]	[redacted] - [redacted]	[redacted]	評価

4.2.2.6 薬物動態学的薬物相互作用（非臨床）

資料番号	資料表題	著者	実施期間（月／日／年）	試験実施場所	評価・参考
4.2.3.2-5	Study 112311 - AMG 145 and Rosuvastatin: 3-Month Combination Toxicology Study in the Cynomolgus Monkey With a 4-Month Recovery Phase	[redacted]	[redacted] - [redacted]	[redacted]	評価

4.2.2.7 その他の薬物動態試験

資料番号	資料表題	著者	実施期間（月／日／年）	試験実施場所	評価・参考
4.2.2.7-1	Study 111721 - Prediction of Pharmacokinetics and Pharmacodynamics of AMG 145 in Humans	[redacted]	[redacted] - [redacted]	111721 is the data analysis report from data obtained from study 111322 111721 - Analysis conducted at Amgen Inc., Seattle, WA 111322 - In-Life conducted at [redacted]	評価
4.2.2.7-2	Study 116111 - Pharmacokinetic and Pharmacodynamic Analysis of Two AMG 145 Formulations in Naïve Male Cynomolgus Monkeys Following a Single Subcutaneous Dose in a Crossover Design	[redacted]	[redacted] - [redacted]	[redacted]	参考
4.2.2.7-3	Study 116654 - Pharmacokinetic and Pharmacodynamic Analysis of Three AMG 145 Formulations in Naïve Male Cynomolgus Monkeys Following a Single Subcutaneous Dose	[redacted]	[redacted] - [redacted]	[redacted]	評価

4.2.3 毒性試験

4.2.3.2 反復投与毒性試験

資料番号	資料表題	著者	実施期間 （月／日／年）	試験実施場所	評価・参考
4.2.3.2-1	Study 112699 - A 28-Day Subcutaneous Injection Toxicity Study of AMG 145 in Hamsters With a 16-Week Treatment-Free Period	[redacted]	[redacted] - [redacted]	[redacted]	評価
4.2.3.2-2	Study 114375 - 3-Month Subcutaneous Injection Extended Pharmacology Study of AMG 145 in Hamsters	[redacted]	[redacted] - [redacted]	[redacted]	評価
4.2.3.2-3	Study 110149 - 6-Week Subcutaneous Toxicity Study of AMG 145 in Cynomolgus Monkeys, With a 21-Week Treatment-Free Period	[redacted]	[redacted] - [redacted]	[redacted]	評価
4.2.3.2-4	Study 110359 - 6-Month Subcutaneous Injection Toxicity Study of AMG 145 in Cynomolgus Monkeys With a 25-Week Treatment-Free Phase	[redacted]	[redacted] - [redacted] Amendment 1: [redacted]	[redacted]	評価
4.2.3.2-5	Study 112311 - AMG 145 and Rosuvastatin: 3-Month Combination Toxicology Study in the Cynomolgus Monkey With a 4-Month Recovery Phase	[redacted]	[redacted] - [redacted]	[redacted]	評価

4.2.3.4 がん原性試験

4.2.3.4.1 長期がん原性試験

資料番号	資料表題	著者	実施期間 （月／日／年）	試験実施場所	評価・参考
4.2.3.4.1-1	Study 114976 - AMG 145: 104-Week Subcutaneous Lifetime Pharmacology Study in Hamsters	[redacted]	[redacted] - [redacted]	[redacted]	評価

4.2.3.5 生殖発生毒性試験

4.2.3.5.1 受胎能及び着床までの初期胚発生に関する試験

資料番号	資料表題	著者	実施期間 （月／日／年）	試験実施場所	評価・参考
4.2.3.5.1-1	Study 114975 - AMG 145: Fertility and Early Embryonic Development Study in the Hamster	[redacted]	[redacted] - [redacted]	[redacted]	評価

4.2.3.5.3 出生前及び出世後の発生並びに母体の機能に関する試験

資料番号	資料表題	著者	実施期間 （月／日／年）	試験実施場所	評価・参考
4.2.3.5.3-1	Study 110370 - AMG 145: Enhanced Pre-Postnatal Development Study in the Cynomolgus Monkey With a 6-Month Postnatal Evaluation	[redacted]	[redacted] - [redacted]	[redacted]	評価

4.2.3.6 局所刺激性試験

資料番号	資料表題	著者	実施期間 （月／日／年）	試験実施場所	評価・参考
4.2.3.6-1	Study 115815 - AMG 145: Subcutaneous Local Tolerance Study in the Hamster	[redacted]	[redacted] - [redacted]	[redacted]	評価
4.2.3.6-2	Study 110151 - Local Tolerance Test in Rabbits After Bolus Intravenous Administration of AMG 145	[redacted]	[redacted] - [redacted] Amendment 1:	[redacted]	評価

4.2.3.7 その他の毒性試験
4.2.3.7.7 その他の試験

資料番号	資料表題	著者	実施期間 （月／日／年）	試験実施場所	評価・参考
4.2.3.7.7-1	Study 112876 - Tissue Cross-Reactivity of Alexa Fluor 488-AMG 145 with Golden Syrian Hamster Tissues In Vitro	[redacted]	[redacted] - [redacted]	[redacted]	評価
4.2.3.7.7-2	Study 110148 - Cross-Reactivity Study of Alexa Fluor 488-AMG 145 with Normal Human and Cynomolgus Monkey Tissues	[redacted]	[redacted] - [redacted]	[redacted]	評価

第4部　非臨床試験報告書

4.3 参考文献

資料番号	著者・表題・出典
4.3-1	Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. *Expert Opin Drug Saf.* 2011;10:373-387.
4.3-2	Abifadel M, Varret M, Rabès J-P, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nat Genet.* 2003;34:154-156.
4.3-3	Agnello V, Gyorgy A, Mutasim E, Knight GB, Zhang Q-X Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor.*Proc Natl Acad Sci.* 1999; 96:12766-12771.
4.3-4	Albecka A, Belouzard S, Op de Beeck A, et al. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. *Hepatology* . 2012;55:998-1007.
4.3-5	Amgen Inc., AMG 145 Preliminary Assessment of Carcinogenic Potential. FDA Submission:SN0038,February, 2011.
4.3-6	Arora R, Liebo M, Maldonado F. Statin-induced myopathy: the two faces of Janus. *J Cardiovasc Pharmacol Ther* . 2006;11:105-112.
4.3-7	Awan Z, Dubuc G, Faraj M, Dufour R, Seidah NG, Davignonb J, Rabasa-Lhoret R, Baass A. The effect of insulin on circulating PCSK9 in postmenopausal obese women. *Clin Biochem* 2014; http://dx.doi.org/10.1016/j.clinbiochem.2014.03.022.
4.3-8	Baass A, Dubuc G, Tremblay M, et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population –based sample of children and adolescents. *Clin Chem.* 2009;55:1637-1645.
4.3-9	Baker SK, Tarnopolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. *Clin Invest Med* . 2001;24:258-272.
4.3-10	Bartels A, O'Donoghue K. Cholesterol in pregnancy: a review of knowns and unknowns. *Obstetric Medicine* 2011; 4:147-151.
4.3-11	Bartosch B, Cosset FL. Studying HCV cell entry with HCV pseudoparticles (HCVpp). *Methods Mol Biol.* 2009;510:279-293.
4.3-12	Beck MJ, Padgett EL, Bowman CJ, et al. Nonclinical juvenile toxicity testing. In: Hood RD, ed. Developmental and Reproductive Toxicology: A Practical Approach. 2nd ed. Boca Raton, FL: Taylor & Francis; 2006;263-327.
4.3-13	Benjannet S, Rhainds D, Essalmani R, et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. *J Biol Chem.* 2004;279:48865-48875.
4.3-14	Bersot TP, Mahley RW, Brown MS, Goldstein JL Interaction of swine lipoproteins with the low density lipoprotein receptor in human fibroblasts. *J Biol Chem.* 1976;251:2395-2398.
4.3-15	Bettermann K, Arnold AM, Williamson J, et al. Statins, risk of dementia, and cognitive function: secondary analysis of the Ginkgo Evaluation of Memory Study. *J Stroke Cerebrovasc Dis* . 2012;21:436-444.
4.3-16	Beydoun MA, Beason-Held LL, Kitner-Triolo MH, et al. Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. *J Epidemiol Community Health* . 2011;65:949-957.
4.3-17	Bingham B, Shen R, Kotnis S, et al. Proapoptotic effects of NARC 1 (=PCSK9), the gene encoding a novel serine proteinase. *Cytometry A* . 2006;69:1123-1131.
4.3-18	Blacklow SC. Versatility in ligand recognition by LDL receptor family proteins: advances and frontiers. *Curr Opin Struct Biol* 2007;17:419–426.
4.3-19	Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. *N Engl J Med.* 2014;370:1809-1819.
4.3-20	Bochem AE, Holleboom AG, Romijn JA, et al. High density lipoprotein as a source of cholesterol for adrenal steroidogenesis: a study in individuals with low plasma HDL-C.*J Lipid Res* . 2013;54:1698-1704.
4.3-21	Brouwers MCGJ, Troutt JS, van Greevenbroek MMJ, et al. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study. *Atherosclerosis* 2011;217:263–267.
4.3-22	Brown MS and Goldstein JL. Lowering LDL – not only how low, but how long?*Science* . 2006;311:1721-1723.
4.3-23	Brown MS, Herz J, Goldstein JL. LDL-receptor structure: Calcium cages, acid baths and recycling receptors. *Nature.* 1997;388:629-630.
4.3-24	Browning JD, Horton JD. Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. *J Lipid Res.* 2010;51:3359-3363.
4.3-25	Brunham LR, Kruit JK, Hayden MR, Verchere LB. Cholesterol in β-cell dysfunction: the emerging connection between HDL cholesterol and type 2 diabetes*Curr Diab Rep* 2010;10:55–60.

4.3-26	Brunham LR, Kruit JK, Verchere CB, Hayden MR. Cholesterol in islet dysfunction and type 2 diabetes *J Clin Invest.* 2008;118:403–408.
4.3-27	Buchwald H, Varco RL, Matts JP et al Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. *New Engl J Med* 1990; 323:946-955.
4.3-28	Burlone ME, Budkowska A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. *J Gen Virol* . 2009;90:1055-1070.
4.3-29	Bussiere JL, Leach MW, Price KD, Mounho BJ, Lightfoot-Dunn R Survey results on the use of the tissue cross-reactivity immuno-histochemistry assay *Regul Toxicol Pharmacol* 2011;59:493-502.
4.3-30	Canuel M, Sun X, Asselin MC, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). *Plos One.* 2013;8:e64145.
4.3-31	Careskey HE, Davis RA, Alborn WE, et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. *J Lipid Res.* 2008;49:394-398.
4.3-32	Cariou B, Langhi C, Le Bras M, et al. Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. *Nutrition & Metabolism* 2013;10:4.
4.3-33	Cariou B, Ouguerram K, Zaïr Y, et al. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. *Arterioscler Thromb Vasc Biol.* 2009;29:2191-2197.
4.3-34	Chang CH, Kusama M, Ono S, et al. Assessment of statin-associated muscle toxicity in Japan: a cohort study conducted using claims database and laboratory information. BMJ Open. 2013 Apr 11;3(4). pii: e002040. doi: 10.1136/bmjopen-2012-002040. Print 2013.
4.3-35	Chen J, Ho S, Hayward M, et al. Comprehensive phenotype of mice carrying PCSK9-Y119X null mutation. *PCSK9 conference* , Nantes, France. 2010.
4.3-36	Chen YQ, Troutt JS, Konrad RJ. PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day. *Lipids* 2014;49:445–455.
4.3-37	Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet.* 2010;376:1670-1681.
4.3-38	Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. *Nat Genet* . 2005;37:161-165.
4.3-39	Cohen JC, Boerwinkle E, Mosley TH, Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. *N Engl J Med* . 2006;354:1264-1272.
4.3-40	Connor WE, Cerquera MT, Connor RW, et al. The plasma lipids, lipoproteins, and diet of the Tarahumara Indians of Mexico. *Amer J Clin Nutr* . 1978:31:1131-1142.
4.3-41	Costet P, Cariou B, Lambert G, et al. Hepatic PCSK9 expression Is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. *J. Biol. Chem* . 2006;281:6211-6218.
4.3-42	Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. *Arch Intern Med* . 2012;172:144-152.
4.3-43	Cunningham D, Danley DE, Geoghegan KF, et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. *Nat Struct Mol Biol.* 2007;14:413-419.
4.3-44	Cuthbert JA, Lipsky PE. Modulation of human lymphocyte responses by low density lipoproteins (LDL): enhancement but not immunosuppression is mediated by LDL receptors. *Proc Natl Acad Sci U S A.* 1984;81:4539-4543.
4.3-45	Cuthbert JA, Lipsky PE. Promotion of human T lymphocyte activation and proliferation by fatty acids in low density and high density lipoproteins. *J Biol Chem.* 1986;261:3620-3627.
4.3-46	Cuthbert JA, Lipsky PE. Provision of cholesterol to lymphocytes by high density and low density lipoproteins: requirement for low density lipoprotein receptors. *J Biol Chem.* 1987;262;7808-7818.
4.3-47	Davis RA, Miyake JH, Hui TY, Spann NJ. Regulation of cholesterol-7 α -hydroxylase: BARElY missing a SHP. *J Lipid Res* . 2002;43:533-543.
4.3-48	Degirolamo C, Modica S, Palasciano G, Moschetta A. Bile acids and colon cancer: Solving the puzzle with nuclear receptors. *Trends Mol Med* . 2011;17:564-572.
4.3-49	Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. *J Am Coll Cardiol* . 2012;60:1888-1898.
4.3-50	Dieckmann M, Dietrich MF, Herz J. Lipoprotein receptors – an evolutionarily ancient multifunctional receptor family. *Biol Chem.* 2010;391:1341-1363.

4.3-51	Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. *J Lipid Res.* 1993;34:1637-1659.
4.3-52	Dietschy JM, Turley SD. Cholesterol metabolism in the brain. *Curr Opin Lipidol* . 2001;12:105-112.
4.3-53	Dietschy JM, Turley SD. Cholesterol metabolism in the central nervous system during early development and in the mature animal. *J Lipids Res* . 2004;45:1375-1397.
4.3-54	Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. *Am J Physiol Cell Physiol.* 2006;291:C1208-1212.
4.3-55	Drevon-Gaillot, E, Perron-Lepage MF, Clement C, Burnett R A review of background findings in cynomolgus monkeys (Macaca fascicularis) from three different geographical origins. *Exp Toxicol Pathol* . 2006;58:77–88.
4.3-56	Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. *Arterioscler Thromb Vasc Biol.* 2004;24:1454-1459.
4.3-57	Espenshade PJ, Hughes AL. Regulation of sterol synthesis in eukaryotes. *Annu Rev Genet.* 2007;41:401-427.
4.3-58	Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. *Pharmacotherapy.* 2009;29:800-811.
4.3-59	Evans MJ, von Hahn T, Tscherne DM, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. *Nature* 2007;446:801–805.
4.3-60	Evers R, Dallas S, Dickmann LJ, Fahmi, Kenny JR, Kraynov E, et al. Critical review of preclinical approaches to investigate cytochrome P450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper. *Drug Metabolism and Disposition* 2013;41:1598-1609.
4.3-61	Ezzati M, Vander Hoorn S, Lopez AD, et al. Chapter 4: Comparative Quantification of Mortality and Burden of Disease Attributable to Selected Risk Factors. In: Lopez AD, Mathers CD, Ezzati M, et al, eds. Global Burden of Disease and Risk Factors. Washington (DC):World Bank; 2006.
4.3-62	FDA Draft Guidance for Industry, "Statistical Aspects of the Design, Analysis, and Interpretation of Chronic Rodent Carcinogenicity Studies of Pharmaceuticals," Center for Drug Evaluation and Research (CDER): Maryland 2001.
4.3-63	FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs 2012 http://www.fda.gov/drugs/drugsafety/ucm293101.htm.
4.3-64	Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. *Neurology* . 2010;74:956-964.
4.3-65	Fisher TS, Lo Surdo P, Pandit S, et al. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. *J Biol Chem.* 2007;282:20502-20512.
4.3-66	Flint OP, Masters BA, Gregg RE, Durham SK. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. *Toxicol Appl Pharmacol.* 1997;145:91-98.
4.3-67	Folsom AR, Peacock JM, Boerwinkle E. Sequence variation in proprotein convertase subtilisin/kexin type 9 serine protease gene, low LDL cholesterol, and cancer incidence. *Cancer Epidemiol Biomarkers Prev.* 2007;16:2455-2458.
4.3-68	Frank RT, Abody KS, Najbauer J. Strategies for enhancing antibody delivery to the brain. *Biochim Biophys Acta* . 2011; 1816:191-198.
4.3-69	Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular Drug Delivery. AAPS Journal (2010) 12:348-360.
4.3-70	Gelzleichter TR, Halpern W, Erwin R, et al. Combined administration of RG7652, a recombinant human monoclonal antibody against PCSK9, and atorvastatin does not result in reduction of immune function. *Tox Sci* . 2014; doi: 10.1093/toxsci/kfu093.
4.3-71	Geyer H, Wuhrer M, Resemann A, Geyer R. Identification and characterization of keyhole limpet hemocyanin N-glycans mediating cross-reactivity with Schistosoma mansoni. *J. Biol. Chem.* 2005;280: 40731–40748.
4.3-72	Go AS, Mozaffarian D, Roger VL, et al on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics – 2013 Update: A Report From the American Heart Association. *Circulation.* 2013;127:e6-e245.
4.3-73	Goedeke L, Fernandez-Hernando C. MicroRNAs: a connection between cholesterol metabolism and neurodegeneration. *Neurobiol Dis* 2014: doi:10.1016/j.nbd.2014.05.034.
4.3-74	Golomb BA, Criqui MH, White H, Dimsdale JE. Conceptual foundations of the UCSD statin study. *Arch Intern Med* 2004;164:153–62.
4.3-75	Goulinet S, Chapman MJ. Plasma lipoproteins in the Golden Syrian hamster (Mesocricetus auratus): heterogeneity of apoB- and apoA-1-containing particles. *J Lipid Res.* 1993;34:943-959.
4.3-76	Graham MJ, Lemonidis KM, Whipple CP, et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. *J Lipid Res* . 2007;48:763-767.
4.3-77	Grefhorst A, McNutt MC, Lagace TA, Horton JD. Plasma PCSK9 preferentially reduces liver LDL receptors in mice. *J Lipid Res.* 2008;49:1303-1311.

4.3-78	Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.*Circulation.* 2004;110:227-239.
4.3-79	Grzych JM, Dissous C, Capron M, Torres S, Lambert PH, Capron A. Schistosoma mansoni shares a protective carbohydrate epitope with keyhole limpet hemocyanin. *J. Exp. Med.* 1987;165, 865–878.
4.3-80	Gu H-M, Adijiang A, Mah M, Zhang D-W. Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding. *J Lipid Res* 2013;54:3345-3357.
4.3-81	Gustafsen C, Kjolby M, Nyegaard M, et al., The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion. *Cell Metabolism* 2014;9:310–318.
4.3-82	Guyton JR, Bays HE, Grundy SM, Jacobsen TA. An assessment by the statin intolerance panel: 2014 update *J Clin Lipidol* 2014; 8:S72–S81.
4.3-83	Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide.*Nat Rev Mol Cell Biol* . 2007; 8:101-112.
4.3-84	Haley P, Perry R, Ennulat D Society of Toxicologic Pathology position paper: best practice guideline for the routine pathology evaluation of the immune system. *Toxicol Pathol* 2005;33:404–407.
4.3-85	Harper CR, Jacobson TA. The broad spectrum of stain myopathy: from myalgia to rhabdomyolysis. *Curr Opin Lipidol.* 2007;18:401-408.
4.3-86	Herz J, Bock HH. Lipoprotein receptors in the nervous system. *Ann Rev Biochem* 2002;71;405-434.
4.3-87	Herz J. Apolipoprotein E receptors in the nervous system. *Curr Opin Lipidol* . 2009;20:190-196.
4.3-88	Hochholzer W, Giugliano RP. Lipid lowering goals: back to nature? *Ther Adv Cardiovasc Dis.* 2010;4:185-191.
4.3-89	Homanics GE, Smith TJ, Zhang SH, et al. Targeted modification of the apolipoprotein B gene results in hypobetalipoproteinemia and developmental abnormalities in mice. *Proc Natl Acad Sci* 1993;90:2389-2393.
4.3-90	Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. *Atherosclerosis.* 2007:193:445-448.
4.3-91	Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. *Trends Biochem Sci.* 2007:32:71-77.
4.3-92	Huang SM, Zhao H, Lee JI, Reynolds K, Zhang L, Temple R, and Lesko LJ Therapeutic protein-drug interactions and implications for drug development. *Clin Pharmacol Ther* 2010;87:497-503.
4.3-93	Hurley WL, Theil PK. Perspectives on immunoglobulins in colostrum and milk. *Nutrients* 2011:3:442-474.
4.3-94	Imano, et al. Low-density lipoprotein cholesterol and risk of coronary heart disease among Japanese men and women: The Circulatory Risk in Communities Study (CIRCS). Preventive Medicine.2011;52:381-386.
4.3-95	International Conference on Harmonisation (ICH) 2005. Harmonised Tripartite Guideline S5 (R2). Guideline for Industry: detection of toxicity to reproduction for medicinal products & toxicity to male fertility.
4.3-96	International Conference on Harmonisation (ICH) 2009. Tripartite Guideline M3 (R2) Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals.
4.3-97	International Conference on Harmonisation (ICH) 2011 Tripartite Guideline S6 (R1) Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals.
4.3-98	Jonas MC, Costantini C, Puglielli L. PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. *EMBO Rep* . 2008;9:916-922.
4.3-99	Jones AR, Shusta EV.Antibodies and the blood-brain barrier In: An Z, ed. *Therapeutic Monoclonal Antibodies: From Bench to Clinic* John Wiley & Sons, Inc. 2009; Ch21:483-502.
4.3-100	Jukema JW, Cannon CP, de Craen AJM, Westendorp RGJ, Trompet S. The controversies of statin therapy: weighing the evidence. *J Am Coll Cardiol* . 2012;60:875–881.
4.3-101	Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. *Proc Natl Acad Sci USA* 1996; 93:5512-5516.
4.3-102	Kamino K, Tillmann T, Boschmann E, Mohr U Age-related incidence of spontaneous non-neoplastic lesions in a colony of Han:AURA hamsters. *Exp Toxicol Pathol* . 2001:53:157-164.
4.3-103	Kantelhardt SR, Wuhrer M, Dennis RD, Doenhoff MJ, Bickle Q, Geyer R. Fuc(alpha1→3)GalNAc-: the major antigenic motif of Schistosoma mansoni glycolipids implicated in infection sera and keyhole-limpet haemocyanin cross-reactivity. Biochem. J. 2002;366:217–223.
4.3-104	Kappelle PJWH, Lambert Gb, Dullaarta RPF. Plasma proprotein convertase subtilisin–kexin type 9 does not change during 24 h insulin infusion in healthy subjects and type 2 diabetic patients. *Atherosclerosis* 2011;214: 432–435.

4.3-105	Keizer RJ, Huitema ADR, Schellens JHM, Beijnen JH. Clinical phramacokinetics of therapeutic monoclonal antibodies. *Clin Pharmacokinet* 2010;49:493-507.
4.3-106	Kenny JR, Liu MM, Chow AT, Earp JC, Evers R, et al. Therapeutic Protein-Drug-Drug Interactions: navigating the knowledge gaps. Highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA Workshop. *The AAPS Journal* . 2013;15(4):933-40.
4.3-107	Kerr TA, Saeki S, Schneider M, et al. Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. *Dev Cell.* 2002;2:713-720.
4.3-108	Kim J, Castellano JM, Jiang H, et al. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. *Neuron* . 2009;64:632-644.
4.3-109	Kita T. Coronary heart disease risk in Japan - an East/West divide? *Eur Heart J* 2004;6(suppl):A8–A11.
4.3-110	Klopfleisch S, Merkler D, Schmitz M, et al. Negative impact of statins on oligodendrocytes and myelin formation in vitro and *in vivo* . *J Neurosci* . 2008;28:13609–13614.
4.3-111	Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia – the MENDEL-2 randomized, controlled phase 3 clinical trial of evolocumab. *J Am Coll Cardiol* . 2014;63:2531-2540
4.3-112	Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. *Lancet.* 2012;380:1995-2006.
4.3-113	Kotowski IK, Pertsemlidis A, Luke A, et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. *Am J Hum Genet* . 2006;78:410-422.
4.3-114	Kuo PT, Hayase K, Kostis JB, Moreyra AE. Use of combined diet and colestipol in long term (7-7.5 years) treatment of patients with type II hyperlipoproteinemia. *Circulation* . 1979;59:199-211.
4.3-115	Kwon HJ, Lagace TA, McNutt MC, et al. Molecular basis for LDL receptor recognition by PCSK9. *Proc Natl Acad Sci USA* . 2008;105:1820-1825.
4.3-116	Kysenius K, Muggalla P, Mätlik K, et al.PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling. *Cell Mol Life Sci* . 2012;69:1903-1916.
4.3-117	Labonté P, Begley S, Guévin C, et al. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. *Hepatology* . 2009;50:17-24.
4.3-118	Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and metabolic determinants of plasma PCSK9 levels. *J Clin Endocrinol Metab* . 2009;94:2537-2543.
4.3-119	Langhi C, Le May C, Gmyr V, et al. PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. *Biochem Biophys Res Commun* . 2009;390:1288-1293.
4.3-120	LaRosa JC, Pedersen TR, Somaratne R, Wasserman SM. Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events. *Am J Cardiol* . 2013;111:1221-1229.
4.3-121	Leach MW, Halpern WG, Johnson CW, et al Use of tissue cross-reactivity studies in the development of antibody-based biopharmaceuticals: history, experience, methodology, and future directions. *Toxicol Pathol.* 2010;38:1138-1366.
4.3-122	Lebrec, H, Molinier B, Boverhof D, et al. The T-cell-dependent antibody response assay in nonclinical studies of pharmaceuticals and chemicals: Study design, data analysis, interpretation. *Regul. Toxicol. Pharmacol.* 2014;69:7-21.
4.3-123	Liu M, Wu G, Baysarowich J, et al. PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain. *J. Lipid Res* . 2010;51:2611-2618.
4.3-124	Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci (2004) 93:2645-2668.
4.3-125	Luo Y, Warren L, Xia D, et al. Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice. *J Lipid Res* . 2009;50:1581-1588.
4.3-126	Mahley RW, Innerarity TL, Pitas RE, Weisgraber KH, Brown JH, Gross E. Inhibition of lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in arginine-rich and B apoproteins. *J Biol Chem* 1977;252:7279-7287.
4.3-127	Mallinson JE, Constantin-Teodosiu D, Glaves PD, et al. Pharmacological activation of the pyruvate dehydrogenase complex reduces statin-mediated upregulation of FOXO gene targets and protects against statin myopathy in rodents. *J. Physiol* . 2012;590:6389-6402.
4.3-128	Martin PL, Weinbauer GF. Developmental toxicity testing of biopharmaceuticals in nonhuman primates: previous experience and future directions. *Int J Toxicol.* 201;29:552-568.
4.3-129	Maxfield FR, Tabas I. Role of cholesterol and lipid organization in disease. *Nature* . 2005;438:612-621.
4.3-130	Mayne J, Dewpura T, Raymond A, et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. *Lipids Health Dis* . 2008;7:22.
4.3-131	Mazumdar B, Banerjee A, Meyer K, Ray R. Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes. *Hepatology* . 2011;54:1149-1156.
4.3-132	Mbikay M, Sirois F, Mayne J, et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. *FEBS Lett.* 2010;584:701-706.

4.3-133	McGuinness B, O'Hare J, Craig D, et al. Cochrane review on "Statins for the treatment of dementia". *Int J Geriatr Psychiatry* . 2013;28:119-126.
4.3-134	McInnes EF, Ernst H, Germann PG. Spontaneous neoplastic lesions in control Syrian hamsters in 6-, 12-, 24-month short-term and carcinogenicity studies. *Toxicol Pathol* . 2013;41:86-97.
4.3-135	McMurry MP, Connor WE, Goplerud CP. The effects of dietary cholesterol upon the hypercholesterolemia of pregnancy. *Metabolism* . 1981;30:869-879.
4.3-136	Miron VE, Zehntner SP, Kuhlmann T, et al. Statin therapy inhibits remyelination in the central nervous system. *Am. J. Pathol.* 2009;174:1880-1890.
4.3-137	Moffat GJ, Retter MW, Kwon G et al. Placental transfer of a fully human IgG2 monoclonal antibody in the cynomolgus monkey, rat and rabbit: a comparative assessment from during organogenesis to late gestation. *Birth Defects Res Part B* 2014; 101:178-188.
4.3-138	Molina S, Castet V, Fournier-Wirth C, et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. *J. Hepatol* . 2007;46:411-419.
4.3-139	Morford LL, Bowman CJ, Blanset DL, et al. Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices. *Birth Defects Res B Dev Reprod Toxicol* . 2011;92:359-380.
4.3-140	Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. *Am J Med* . 2000;108:538-546.
4.3-141	Muldoon MF, Ryan CM, Sereika SM, et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. *Am J Med* . 2004;117:823-829.
4.3-142	NDA 21-366: CDER Approval Package for Crestor (rosuvastatin calcium) tablets. 2003.
4.3-143	Nguyen MA, Kosenko T, Lagace TA. Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts. *J Lipid Res.* 2014;55:266-275.
4.3-144	Niesen M, Bedi M, Lopez D. Diabetes alters LDL receptor and PCSK9 expression in rat liver. *Arch Biochem Biophys* . 2008;470:111-115.
4.3-145	Ooba N, Sato T, Wakana A, et al. A prospective stratified case-cohort study on statins and multiple adverse events in Japan. PLoS One. 2014 e96919. doi: 10.1371/journal.pone. 0096919. eCollection 2014.
4.3-146	折井孝男、下堂薗権洋、石本敬三、他. 平成21年度学術委員会学術第2小委員会報告 薬剤疫学的手法を利用した医薬品適正使用に関する研究（最終報告）. 日本病院薬剤師会雑誌, 2010; 46, 993-997.
4.3-147	Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. *Pharmacotherapy* . 2001;21:767-769.
4.3-148	Parker BA, Polk DM, Rabdiya V, et al. Changes in memory function and neuronal activation associated with atorvastatin therapy. *Pharmacotherapy.* 2010;30(6):236e-240e.
4.3-149	Parker RA, Garcia R, Ryan CS, et al. Bile acid and sterol metabolism with combined HMG CoA reductase and PCSK9 suppression. *J Lipid Res* . 2013;54:2400-2409.
4.3-150	Persson L, Cao G, Ståhle L,et al. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. *Arterioscler Thromb Vasc Biol* . 2010;30:2666-2672.
4.3-151	Persson L, Gälman C, Angelin B, Rudling M. Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors. *Endocrinology* . 2009;150:1140-1146.
4.3-152	Peticca P, Raymond A, Gruslin A, et al. Human serum PCSK9 Is elevated at parturition in comparison to nonpregnant subjects while serum PCSK9 from umbilical cord blood is lower compared to maternal blood. *ISRN Endocrinol* . 2013, 341632.
4.3-153	Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. *Science* . 1998;282:938-941.
4.3-154	Pitas RE, Boyles JK, Lee SH, et al. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E (LDL) receptors in the brain. *J Biol Chem* . 1987;262:14352-14360.
4.3-155	Podulso JF, Curran GL, Berg CT. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc Natl Acad Sci USA. 1994;91:5705-5709
4.3-156	Poduslo JF, Curran GL, Berg CT. Macromolecular permeability across the blood-brain barriers. *Proc Natl Acad Sci USA* . 1994 ;91:5705-5709.
4.3-157	Poirier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. *J Biol Chem* . 2008;283:2363-2372.
4.3-158	Poirier S, Prat A, Marcinkiewicz E, et al. Implication of the convertase NARC-1/PCSK9 in the development of the nervous system. *J. Neurochem* . 2006;98:838-850.
4.3-159	Postmus I, Trompet S, de Craen AJ, et al. PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population. *J Lipid Res* . 2013;54:561-566.

4.3-160	Pour P, Kmoch N, Greiser E, Mohr U, Althoff J, Cardesa A. Spontaneous tumors and common diseases in two colonies of Syrian hamsters. I. Incidence and sites. *J Natl Cancer Inst* 1976a;56:931-935.
4.3-161	Pour P, Mohr U, Althoff J, Cardesa A, Kmoch N. Spontaneous tumors and common diseases in two colonies of Syrian hamsters. III. Urogenital system and endocrine glands*J Natl Cancer Inst* 1976b;56:949-961.
4.3-162	Pour P, Mohr U, Althoff J, Cardesa A, Kmoch N. Spontaneous tumors and common diseases in two colonies of Syrian hamsters.. IV. Vascular and lymphatic systems and lesions of other sites *J Natl Cancer Inst,* 1976c;56:963-973.
4.3-163	Pour P, Mohr U, Cardesa A, Althoff J, Kmoch N (1976d) Spontaneous tumors and common diseases in two colonies of Syrian hamsters.. II. Respiratory tract and digestive system *J Natl Cancer Inst* 1976b;56:937-948.
4.3-164	Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. *Circulation.* 2012;126:2408-2417.
4.3-165	Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. *Diabetes Care* . 2009;32:1924-1929.
4.3-166	Ramanathan A, Gusarova V, Kyratsous C. Role of alirocumab (proprotein convertase subtilisin/kexin type 9 antibody) on CD81 levels and hepatitis C virus entry into hepatocytes. [abstract] *American Heart Association* 2013; Abstract 12052.
4.3-167	Rashid S, Curtis DE, Garuti R, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. *Proc Natl Acad Sci USA.* 2005;102:5374-5379.
4.3-168	Reddy SS, Connor TE, Weeber EJ, Rebeck W. Similarities and differences in structure, expression, and functions of VLDLR and ApoER2. *Mol Neurodegener.* 2011;6:30.
4.3-169	Reynolds CA, Hong MG, Eriksson UK, et al. Analysis of lipid pathway genes indicates association of sequence variation near SREBF1/TOM1L2/ATPAF2 with dementia risk. *Hum Mol Genet.* 2010;19:2068-2078.
4.3-170	Rhinn H, Fujita R, Qiang L, et al. Integrative genomics identifies APOE e4 effectors in alzheimer's disease. *Nature.* 2013;500:45-50.
4.3-171	Richardson K, Schoen M, French B, et al. Statins and cognitive function: a systematic review. *Ann Intern Med* . 2013;159:688-697.
4.3-172	Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. *J Am Coll Cardiol* . 2005;46:1855-1862.
4.3-173	Rojas-Fernandez CH, Goldstein LB, Levey AI, et al. An assessment by the Statin Cognitive Safety Task Force: 2014 update *J Clin Lipidol* . 2014;8:S5-S16.
4.3-174	Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the Statin Muscle Safety Task Force: 2014 update. *J Clin Lipidol* . 2014;8:S58-S71.
4.3-175	Roubtsova A, Munkonda MN, Awan Z, et al. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. *Arterioscler Thromb Vasc Biol.* 2011;31:785-791.
4.3-176	Rousselet E, Marcinkiewicz J, Kriz J, et al. PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke. *J Lipid Res.* 2011;52:1383-1391.
4.3-177	Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. *Annu Rev Biochem.* 2003;72:137-174.
4.3-178	Saher G, Simons M. Cholesterol and myelin biogenesis. In: J.R. Harris (ed.), *Cholesterol Binding and Cholesterol Transport Proteins Subcellular Biochemistry* . Springer Science+Business Media B.V. 2010;51:489-508. DOI 10.1007/978-90-481-8622-8_18.
4.3-179	Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? *Curr Opin Cardiol.* 2011;26:342-347.
4.3-180	Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. *Lancet* . 2010;375:735-742.
4.3-181	Sattar N, Taskinen MR. Statins are diabetogenic – myth or reality? *Atheroscler Suppl.* 2012;13:1-10.
4.3-182	Scarselli E, Ansuini H, Cerino R, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. *EMBO J* . 2002;21:5017-5025.
4.3-183	Schaefer WH, Lawrence JW, Loughlin AF, et al. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. *Toxicol Appl Pharmacol* . 2004;194:10-23.
4.3-184	Schmidt RJ, Beyer TP, Bensch WR, et al. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. *Biochem Biophys Res Commun.* 2008;370:634-640.

4.3-185	Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S.Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. *Clin Pharmacol Therap* 2011;89:735-740.
4.3-186	Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9: A key modulator of cardiovascular health. *Circ Res* . 2014;114:1022-1036.
4.3-187	Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. *Proc Natl Acad Sci USA* . 2003;100:928-933.
4.3-188	Seidah NG, Poirier S, Denis M, et al. Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. *PLoS One* . 2012;7:e41865.
4.3-189	Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. *Nat Rev Drug Discov* . 2012;11:367-383.
4.3-190	Sellers R, Morton D, Michael B, et al. Society of Toxicologic Pathology position paper: organ weight recommendations for toxicology studies. *Toxicol Pathol.* 2007;35:751-755.
4.3-191	Sestak K, Merritt CK, Borda J, et al. Infectious agent and immune response characteristics of chronic enterocolitis in captive rhesus macaques. *Infect Immun.* 2003;71:4079-4086.
4.3-192	Shan L, Pang L, Zhang R, et al. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. *Biochem Biophys Res Commun* . 2008;375:69-73.
4.3-193	Sharotri V, Collier DM, Olson DR, et al. Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9). *J Biol Chem.* 2012;287:19266-19274.
4.3-194	Smith ME. The turnover of myelin in the adult rat. *Biochim Biophys Acta.* 1968;164:285-293.
4.3-195	Spoor MS, Radi ZA, Dunstan RW. Characterization of age- and gender-related changes in the spleen and thymus from control cynomolgus macaques used in toxicity studies. *Toxicol Pathol* . 2008;36:695-704.
4.3-196	Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). *JAMA.* 1986;256:2823-2828.
4.3-197	Statistics Canada. Canadian Health Measures Survey, 2009 to 2011. 13 February 2013 version. Available at: http://www.statcan.gc.ca/pub/82-625-x/2012001/article/11732- eng.htm.
4.3-198	Statistics Canada. Ten leading causes of death by selected age groups, by sex, Canada — All ages – 2009. 25 July 2012 version. Available at: http://www.statcan.gc.ca/pub/84- 215-x/2012001/tbl/t001-eng.htm.
4.3-199	Staudinger JL, Goodwin B, Jones SA, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. *Proc Natl Acad Sci USA.* 2001;98:3369-3374.
4.3-200	Stein EA, Honarpour N, Wasserman SM, et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. *Circulation* . 2013;128:2113-2120.
4.3-201	Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. *Proc Natl Acad Sci U S A* . 1993;90:8098-8102.
4.3-202	Swiger KJ, Manalac RJ, Blumenthal RS, et al. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. *Mayo Clin Proc* . 2013;88:1213-1221.
4.3-203	Syed GH, Tang H, Khan M, et al. Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation. *J Virol* . 2014;88:2519-2529.
4.3-204	Tabrizi M, Bornstein GG, Suria H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS Journal 43 (2010) 12:33-43.
4.3-205	Taha DA, De Moor CH, Barrett DA, Gershkovich P. Translational insight in to statin-induced muscle toxicity: from cell culture to clinical studies. *Transl Res* . 2014; S1931-5244(14)00034-6. doi: 10.1016/j.trsl.2014.01.013.
4.3-206	Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. *Cell* . 2005;120:545-555.
4.3-207	Thiel MA, Coster DJ, Williams KA. The potential of antibody-based immunosuppressive agents for corneal transplantation. Immunol Cell Biol (2003) 81:93-105.
4.3-208	Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. *JAMA* . 2003;289:1681-1690.
4.3-209	Thompson PD, Parker B. Statins, exercise, and exercise training. *J Am Coll Cardiol.* 2013;62:715-716.
4.3-210	Tolonen H, Keil U, Ferrario M, et al. Prevalence, awareness and treatment of hypercholesterolaemia in 32 populations: results from the WHO MONICA Project. *Int J Epidemiol* . 2005;34:181-192.
4.3-211	Tomkin GH, Owens D. The chylomicron: relationship to atherosclerosis. *Int J Vasc Med.* 2012;2012:784536.

4.3-212	Triguero D, Buciak JB, Yang J, Pardridge WM. Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein. *Proc Natl Acad Sci USA.* 1989; 86:4761-4765.
4.3-213	Trompet S, van Vliet P, de Craen AJ, et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. *J Neurol* . 2010;257:85-90.
4.3-214	Unger RH. Lipotoxic diseases. *Annu Rev Med* . 2002;53:319-336.
4.3-215	Vaklavas C, Chatzizisis YS, Ziakas A, et al. Molecular basis of statin-associated myopathy. *Atherosclerosis* . 2009;202:18-28.
4.3-216	Van de Perre P. Transfer of antibody via mother's milk. *Vaccine.* 2003;21:3374-3376
4.3-217	Vargas HM, Bass AS, Breidenbach A, et al. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. *J Pharmacol Toxicol Methods.* 2008;58:72-76.
4.3-218	Vassar R. BACE1: the beta-secretase enzyme in Alzheimer's disease. *J Mol Neurosci.* 2004;23:105-114.
4.3-219	Vere CC, Streba CT, Streba L, Rogoveanu I. Lipid serum profile in patients with viral liver cirrhosis. *Med Princ Pract* . 2012;21:566-568.
4.3-220	Vergeer M, Korporaal SJ, Franssen R, et al. Genetic variant of the scavenger receptor B1 in humans. *N Engl J Med* . 2011;364:136-145.
4.3-221	Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. *Pharmacotherapy* . 2003;23:871-880.
4.3-222	Waldmann TA, Strober W. Metabolism of immunoglobulins. *Prog Allergy* . 1969;13:1-110.
4.3-223	Weinbauer GF, Chellman GJ, Rasmussen AD, Vogelwedde E. Use of primate pediatric model. In Hoberman AM and Lewis EM, ed. *Pediatric Non-Clinical Drug Testing. Principles, Requirements and Practices.* John Wiley & Sons, Inc. 2012; Ch13:255-279.
4.3-224	Weinbauer GF, Luft J, Fuchs A. The enhanced pre- and postnatal development study for monoclonal antibodies. *Methods Mol Biol.* 2013;947:185-200.
4.3-225	Westwood FR, Bigley A, Randall K, et al. Statin-induced muscle necrosis in the rat: distribution, development, and fiber selectivity. *Toxicol Pathol.* 2005;33:246-257.
4.3-226	Westwood FR, Scott RC, Marsden AM, et al. Rosuvastatin: characterization of induced myopathy in the rat. *Toxicol Pathol* . 2008;36:345-352.
4.3-227	WHO. Global atlas on cardiovascular disease prevention and control. Cardiovascular Diseases (CVD). Fact Sheet Number 317. Geneva, World Health Organization, 2011b.
4.3-228	WHO. Global Status Report on Noncommunicable Diseases 2010. Chapter 1. Burden: mortality, morbidity, and risk factors. Geneva, Switzerland: WHO; 2011a.
4.3-229	Woollett LA. Maternal cholesterol in fetal development: transport of cholesterol from the maternal to the fetal circulation. *Am J Clin Nutr.* 2005;82:1155-1161.
4.3-230	Wu JE, Basso F, Shamburek RD, et al. Hepatic ABCG5 and ABCG8 overexpression increases hepatobiliary sterol transport but does not alter aortic atherosclerosis in transgenic mice. *J Biol Chem.* 2004;279:22913-22925.
4.3-231	Yu JT, Tan L, Hardy J. Apolipoprotein E in Alzheimer's Disease: An update. *Annu Rev Neurosci.* 2014; DOI: 10.1146/annurev-neuro-071013-014300.
4.3-232	Yu YJ, Watts RJ. Developing therapeutic antibodies for neurodegenerative disease. *Neurotherapeutics* . 2013;10:459-472.
4.3-233	Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. *Hepatology.* 2008;48:646-654.
4.3-234	Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. *Neuroepidemiology* . 2004;23:94-98.
4.3-235	Zandi PP, Sparks DL, Khachaturian AS, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. *Arch Gen Psychiatry* . 2005;62:217-224.
4.3-236	Zhang DW, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. *J Biol Chem* . 2007;282:18602-18612.
4.3-237	Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. *Am J Hum Genet.* 2006;79:514-523.
4.3-238	Zhong Z, Ewers M, Teipel S, et al. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. *Arch Gen Psychiatry* . 2007;64:718-726.
4.3-239	Zhou B, Teramukai S, Fukushima M. Prevention and treatment of dementia or Alzheimer's disease by statins: a meta-analysis. *Dement Geriatr Cogn Disord* . 2007;23:194-201.
4.3-240	Zhou H, Davis HM. Risk-based strategy for the assessment of pharmacokinetic drug–drug interactions for therapeutic monoclonal antibodies. *Drug Disc Today* 2009;14:891-898.
4.3-241	Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. *Neuron* . 2008;57:178-201.